Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Multi-omics approaches to lower the barriers to sustainable production of plant natural products with relevance to human health

Award Number: R01AT012783
ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2028

Group Awards By:

View Award Description

Multi-omics approaches to lower the barriers to sustainable production of plant natural products with relevance to human health - PROJECT SUMMARY Plants synthesize complex molecules for defense and signaling using specialized metabolic pathways. These plant natural products enhance their own evolutionary fitness and many of these molecules have been used with great success as pharmaceuticals to treat a wide range of human diseases as exemplified by Paclitaxel and Vinorelbine. However, our access to plant specialized metabolites can be limited, as these molecules are often produced in small amounts as part of complex mixtures and restricted to specific cell-types. While metabolic engineering and synthetic biology has the potential to improve our access to these compounds, these approaches require in-depth knowledge of the biosynthetic genes, transporters, and/or regulatory elements of the specific pathway. Next-generation omics technologies have made elucidation of plant natural product pathways more streamlined over the last decade, yet the discovery of plant natural product genes remains challenging relative to that in microbial systems. As a consequence, successful examples of metabolic engineering to improve access to the wealth of pharmacologically active molecules encoded in plant genomes are still few in number. For example, while the plant anti-cancer agent vinblastine has been reconstituted in yeast, the titers are not commercially viable. We have recently developed a single-cell omics-enabled, genome-to-pathway discovery pipeline that accelerates the discovery of natural product biosynthetic pathway genes and their associated regulatory sequences, including transcription factors and cis-regulatory elements. In Aim 1, we will prepare single cell- omics datasets from plant materials for pathway discovery of eight key plant natural products with anti-pain, anti- inflammatory, anti-malarial, and anti-cancer activity. In Aim 2, we will select and validate biosynthetic pathway genes for these compounds in N. benthamiana. New and innovative metabolic engineering strategies for improving access to plant natural products are still needed. In Aim 3, cell-type specific regulatory sequences for these eight biosynthetic pathways will be identified. In Aim 4, synthetic biology will bes used to engineer Catharanthus roseus callus-derived suspension cultures to produce anhydrovinblastine and a subset of the eight natural products from this study. Single-cell omics will be used to examine the heterogeneity of natural product production in populations of wild-type and engineered C. roseus suspension culture cells. Even if commercially appropriate cultures are not developed within the scope of this proposal, this project will provide the first rigorous omics datasets on a plant cell culture system. In summary, the state-of-the-art omics approach in this project will lower the barrier for gene discovery of plant-derived natural products. Utilization of synthetic biology approaches empowered by cell-type-specific knowledge of biosynthetic pathways will enable a renaissance in the sustainable production of clinically-relevant compounds in plant suspension culture.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $523,612 )
2026	2026	UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.	310 E CAMPUS RD RM 409	ATHENS	GA	30602	CLARKE	USA	Research and Training in Complementary and Integrative Health	000	3	4/29/2026	NON-COMPETING CONTINUATION	$523,612
														Subtotal = $523,612

Issue Date FY: 2025 ( Subtotal = $485,272 )
2025	2025	UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.	310 E CAMPUS RD RM 409	ATHENS	GA	30602	CLARKE	USA	Research and Training in Complementary and Integrative Health	000	2	12/6/2024	NON-COMPETING CONTINUATION	$485,272
														Subtotal = $485,272

Issue Date FY: 2024 ( Subtotal = $529,426 )
2024	2024	UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.	310 E CAMPUS RD RM 409	ATHENS	GA	30602	CLARKE	USA	Research and Training in Complementary and Integrative Health	000	1	2/21/2024	NEW	$529,426
														Subtotal = $529,426

Grand Total All Awards = $1,538,310

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Multi-omics approaches to lower the barriers to sustainable production of plant natural products with relevance to human health

Award Number: R01AT012783

ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer